(Q53570884)

15 May 2018

title

From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. (English)

1 reference

15 May 2018

author name string

Makino I

series ordinal

1

1 reference

15 May 2018

Tanaka H

series ordinal

2

1 reference

15 May 2018

publication date

1 June 1998

1 reference

15 May 2018

Journal of Gastroenterology and Hepatology

published in

1 reference

15 May 2018

volume

13

1 reference

15 May 2018

issue

6

1 reference

15 May 2018

page(s)

659-664

1 reference

15 May 2018

Dissolution of Cholesterol Gallstones by Chenodeoxycholic Acid

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Dissolution of cholesterol gallstones by ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

The developmental process from micelle to liquid crystal in the ursodeoxycholate, phosphatidylcholine and cholesterol solution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

The physicochemical basis of cholesterol gallstone formation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyltranspeptidase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Present status of autoimmune hepatitis in Japan--correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

The immunosuppressive effect of ursodeoxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Chenodeoxycholic acid-dependent induction of major histocompatibility complex class I mRNA expression in a human hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

The steroid and thyroid hormone receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

Gene regulation by steroid hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1998.TB00707.X

10.1111/J.1440-1746.1998.TB00707.X

21 January 2018

Identifiers

DOI

1 reference

15 May 2018

PubMed ID

9715413

1 reference

15 May 2018